Replimune Group, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
REPL$23.28+4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except share amounts)
| Common stock · Additionalpaid-incapital · Accumulateddeficit · Accumulatedothercomprehensiveincome · Totalstockholders’equity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||||||
| Balances as of March 31, 2025 | 77,085,024 | $77 | $1,358,897 | $(948,579) | $5,448 | $415,843 | ||||||
| Foreign currency translation adjustment | — | — | — | — | (938) | (938) | ||||||
| Unrealized loss on short-term investments | — | — | — | — | (269) | (269) | ||||||
| Exercise of stock options | 966 | — | 8 | — | — | 8 | ||||||
| Vesting of RSUs | 721,184 | 1 | 1 | — | — | 2 | ||||||
| Stock-based compensation expense | — | — | 8,762 | — | — | 8,762 | ||||||
| Net loss | — | — | — | (86,693) | — | (86,693) | ||||||
| Balances as of June 30, 2025 | 77,807,174 | 78 | 1,367,668 | (1,035,272) | 4,241 | 336,715 | ||||||
| Balances as of March 31, 2024 | 61,415,105 | $61 | $1,070,874 | $(701,282) | $4,855 | $374,508 | ||||||
| Issuance of prefunded warrants to purchase common stock, net of issuance costs | — | — | 48,500 | — | — | 48,500 | ||||||
| Issuance of common stock in connection with private placement, net of placement agent fees and offering costs | 5,668,937 | 6 | 48,198 | — | — | 48,204 | ||||||
| Foreign currency translation adjustment | — | — | — | — | (432) | (432) | ||||||
| Unrealized loss on short-term investments | — | — | — | — | (99) | (99) | ||||||
| Exercise of pre-funded warrants | 739,225 | 1 | — | — | — | 1 | ||||||
| Exercise of stock options | 22,860 | — | 66 | — | — | 66 | ||||||
| Vesting of RSUs | 463,841 | — | — | — | — | — | ||||||
| Stock-based compensation expense | — | — | 9,475 | — | — | 9,475 | ||||||
| Net loss | — | — | — | (53,772) | — | (53,772) | ||||||
| Balances as of June 30, 2024 | 68,309,968 | 68 | 1,177,113 | (755,054) | 4,324 | 426,451 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.